📣 Arjan van Manen joins us as Head of Business Development. With 20+ years in clinical strategy, he’s focused on closing the gap between clinical need & investment risk. 🤝🏽 Understanding challenges to deliver data-driven, tailored solutions. 📍At ESCMID? Connect with him! 🔗https://bit.ly/ArjanEcraid

📝 Have insights on ethical review procedures for cohort studies? Participate in this survey (15–20 min) to help improve the efficiency of ethical review processes for cohort studies during public health emergencies. www.id-care.net/post/share-y...

📣 Our March newsletter is out! 🔬 Join us at #ESCMIDGlobal2026 in Munich (Booth F21) 🎓 5th Young Investigator Workshop – 19 April, 09:30 CEST 🏥 ECRAID-Prime trial advances patient-centric research Plus new publications & collaborations. 👉🏽Subscribe now: mailchi.mp/ecraid/newsl...

Join the Young Investigator Workshop at #ESCMIDGlobal 2026 for practical insights and science you can actually use! Early-career investigators are driven to deliver meaningful research, but navigating the “how” isn’t always straightforward. 📍 Room 2 (ICM Ground Floor) 👉 bit.ly/4uKdN0r

Looking ahead to #ESCMIDGlobal 2026 in Munich, we’re reflecting on the energy & collaboration from Vienna last year. Great to connect with so many experts & partners advancing ID research. Excited to continue these conversations in Munich. Will you be there? Visit us at booth F21: bit.ly/474r0qy

📢Ecraid has joined the WHO Global Clinical Trials Forum. This milestone boosts our mission to advance high-quality research, strengthen global collaboration, and improve trial readiness, data sharing, and patient outcomes worldwide. Read more: bit.ly/418YDEh #GlobalHealth @whowpro.bsky.social

A recent article published in Contemporary Clinical Trial Communications evaluates the considerations raised during the regulatory & ethics review of five ID #PlatformTrials: #ECRAIDPrime, #RECLAIM, #REMAPCAP, #RECOVERY, and #SNAP. Explore the full article here bit.ly/4v0qSCH #TrialInnovation

📍Visit us at booth #F21 at #ESCMID Global 2026 in Munich! Innovation in ID requires strong partnerships. 🔬At Ecraid we're committed to building & growing collaborations across Europe to strengthen clinical research & tackle AMR. Meet our team & explore how we can work together: bit.ly/474r0qy

Two new #ECRAIDBase publications available! 🫁 The first provides a detailed narrative of the POS-VAP study. 📊 The second asks how do we measure knowledge, attitudes, & practices around biomedical data reuse? Explore the papers bit.ly/4beBA0z #ClinicalTrials #VAP #DataScience #CriticalCare

Will you be at #ESCMIDGlobal 2026 in Munich? Visit Ecraid at booth F21. As AMR and emerging infections continue to challenge healthcare systems, collaboration across academia, clinical networks & industry is essential. Interested in connecting? Book a meeting: bit.ly/474r0qy #InfectiousDiseases

The world of #ClinicalResearch is evolving fast - are you ready to grow with it? Join our 5th Young Investigator Workshop at #ESCMIDGlobal2026. A dedicated space for early-career researchers to gain practical, real-world insights you won't find in textbooks: bit.ly/4uKdN0r @escmid.bsky.social

At the AMR Conference in Basel, Ecraid announced a new partnership with @incate.bsky.social. Together we’re connecting clinical research & translational innovation to accelerate antimicrobial development & strengthen the pipeline against #AMR. Read how we combine our strengths: bit.ly/INCATE-Ecraid

Last Friday, @christophercbutler.bsky.social presented at the #RethinkingClinicalTrials webinar (hosted by @dcrinews.bsky.social and @pctcollaboratory.bsky.social). He highlighted pre-pandemic studies & how ECRAID-Prime & ECRAID-Base are strengthening #Europe’s response to future health threats.

🫱🏼‍🫲🏻 We're proud to present the #PrIMAVeRaProject and our #perpetualobervationalstudies at the 7th @amr-accelerator.bsky.social Cross-Project Meeting held in Basel yesterday. We look forward to seeing everyone again at the PrIMAVeRa stakeholder meeting at #ESCMID2026! @elskesieswerda.bsky.social

What if, in the next infectious disease outbreak, patients are: 🤒 Too sick to travel? 🦠 Unable to visit clinics & traditional research sites? 🏔️ Living in remote or underserved areas? The #ECRAIDPrime trial demonstrates that research does not need to stop. Trials can come to the patient.

New collaboration! We’re proud to announce that Ecraid has officially partnered with INCATE. We will play a key role in supporting, educating & guiding early-stage translational projects, strengthening their path toward successful development of new treatment modalities to combat #AMR.

See you at #ESCMIDGlobal2026 in Munich! 🇩🇪 Find us in the Exhibition Hall (Booth F21), and throughout the scientific programme. Our committed colleagues will present Ecraid-driven science in posters, presentations and talks during the congress. More details soon! @escmid.bsky.social

📢 Meet us at the AMR Conference in Basel! Our CEO @lenniederde.bsky.social & Head of BD Arjan van Manen will be attending. Ecraid is looking forward to discuss future collaborations with you! 📅 Book a meeting with us via the PartneringOne platform: lnkd.in/edKBRYf

Ecraid’s second newsletter of the year is out! Discover the latest updates, studies, publications & upcoming events! Inside this edition: 🔍Highlights from the Ecraid Foundation Science Meeting 🚀The launch of BE READY NOW And much more... 👉🏽Stay informed, subscribe now: bit.ly/EcraidNewsFe...

📢 Meet us at the AMR Conference in Basel! Our CEO @lenniederde.bsky.social & Head of BD Arjan van Manen will be attending. Ecraid is looking forward to discuss future collaborations with you! 📅 Book a meeting with us via the PartneringOne platform: lnkd.in/edKBRYf

🇪🇺 Our recent CoMeCT project Sustainability Workshop discussed the future development of the project’s coordination activities and its role in #BEREADY project to strengthen #clinicalresearch readiness for #publichealth emergencies. Read more on 👉🏽 www.ecraid.eu/news/coordin...

Lennie Derde speaks about #PandemicPreparedness in @horizoneu.bsky.social Magazine She explains the importance of a permanent clinical research infrastructure across Europe to tackle emerging #InfectiousDiseases & #AntimicrobialResistance projects.research-and-innovation.ec.europa.eu/en/horizon-m...

The BE READY NOW European Partnership is live! 🚀 Ecraid is supporting this initiative by building 'ever-warm' research networks & FAIR data protocols, ensuring Europe is ready to respond to threats with unprecedented speed. 🔗 Full details bit.ly/463tpBe #PandemicPreparedness #ClinicalResearch

Today in #InternationalEducationDay Ecraid is more than an organisation focused on clinical research. It is a place where young and early-career talent and experienced experts – from both academia and industry – connect to collaborate and learn. Explore our Education Page: ecraid.eu/education

📣 The first site has been activated in the PIPELINE-RSV International trial & is now open for recruitment at St George's University Hospitals NHS Foundation Trust in London! Congratulations to everyone involved in reaching this important milestone! #RSV #Vaccination #MonoclonalAntibodies #mAbs

🚨 Last Call: Ecraid Foundation Science Meeting! Today is your final chance to register for this academic event bringing together leading experts from academia, industry, and the public sector. Can’t attend this time? You can still stay connected! Subscribe to our newsletter: bit.ly/EcraidJan26

📢 Ecraid Foundation Science Meeting: registration deadline extended! Join industry leaders, researchers, clinicians & policy experts to discuss cutting-edge science & collaboration in infectious diseases and clinical research. Accredited by NVMM (11 points) and ABIC www.eventbrite.nl/e/ecraid-fou...

Read this research letter on the re-emergence of M. pneumoniae 👉 publications.ersnet.org/content/erjo... This unexpected surge emphasises the need for continued attention to respiratory #pathogen dynamics and their impact on #PatientCare and #PublicHealth responses. @europeanrespsoc.bsky.social

📢 Programme Update: Meet our Speakers! We’ve added new speakers to the Ecraid Foundation Science Meeting - each track now features a detailed programme. Featured speakers include: Pontus Naucler (Karolinska Institute) Kristina Rudd (Pittsburgh University) & industry leaders. 👉🏼 Register: bit.ly/EFSM

🤧 The EU-funded #ECRAIDPrime trial has randomised its first 3 remote patients in the #UK this flu season — launching a patient-centric approach to expand access and community participation. This is a big step for infectious disease trials in #PrimaryCare and #Europe. 🎉 Congrats to the Oxford team!

Europe’s first #adaptiveplatformtrial for #COVID19 and COVID-like illness in the community launched its third treatment arm, marking an important step forward in Europe's pandemic preparedness. Read about this pioneering trial on www.ecraid.eu/news/primary...

3 years on, Ecraid is firmly embedded in Europe’s infectious diseases research ecosystem. In this interview with Prof. Sir @peterhorby.bsky.social from the Pandemic Sciences Institute, Oxford, he discusses Ecraid’s clinical trial infrastructure & future challenges. www.ecraid.eu/articles/eur...

🚨 The countdown is on for the Ecraid Foundation Science Meeting 2026! Join us for high-impact scientific exchange and collaborative networking. 🥼 Access to infectious disease experts 🏆 Accreditation by ABIC and NVMM Don’t miss your chance to register: www.eventbrite.nl/e/ecraid-fou...

🎧Recording available! Tune into this webinar in collaboration with @europeanrespsoc.bsky.social on #PandemicPreparedness 👇 channel.ersnet.org/media-114951...

As we close out 2025, we look back on a truly landmark year for Ecraid: one defined by growth, collaboration, and impact. Thank you to our partners, collaborators, sites, investigators, and team members for your commitment and trust. Happy holidays, and all the best for the year ahead 🌟

🎉 Amazing milestones reached in three of our perpetual observational studies (POS)! We are tremendously proud of ALL the site teams behind these studies, for making it happen as 2025 comes to an end - a great way to wrap up the year! Thank you! ecraid.eu/ecraid-base/...

Announcing Module 2 of the Ecraid x @ESCMID online course on Biomedical Data & Sample Governance: 'How to design your data governance framework' in collaboration with CoMeCT, IDDO, CERCLE, @who.int and @tghn-news.bsky.social 🎧👉 www.escmid.org/education/ed... #DataGovernance #EpidemicPreparedness

📩Our final newsletter of 2025 is out! As we close 2025, we also say farewell to our CEO, @marcbonten.bsky.social. We are proud of what we have achieved together over the years & look ahead with confidence to 2026, welcoming @lenniederde.bsky.social onboard! Read more & subscribe: bit.ly/Dec25Ecraid

The rationale & design of the #PNEUMO study Europe was recently published! 👉 bit.ly/3MBR6d4 Now in its final year, the studies primary goal is to estimate the incidence of pneumococcal #pneumonia & serotype prevalence among adults in Europe. #ClinicalTrials #InfectiousDiseases #ResearchSky #IDSky

Join the Ecraid Foundation Science Meeting on 2 February 2026 in Utrecht! This two-day academic event brings together leading experts, researchers & infectious disease opinion leaders from across Europe to advance clinical research in ID. More info & tickets: www.eventbrite.nl/e/ecraid-fou...

Trainings, talent & top science: the last Ecraid Learning Newsletter of the year is out! Filled to the brim with exciting courses, testimonials from participants at past ones, freshly-published science and interesting interviews & blogs! 👉🏽https://bit.ly/LearningDecEcraid

Ecraid joins the #PrIMAVeRa_AMR Consortium to accelerate #AMR modelling! This strategic partnership is a powerful step forward in the fight against #AntimicrobialResistance. 👉🏽Learn more about this vital collaboration & its impact on public health: www.ecraid.eu/news/ecraid-... #StopSuperbugs

Ventilator-associated pneumonia can be a challenge to study in traditional randomised controlled trials due to low patient and event numbers. This recent paper explores whether adaptive trial designs can make VAP prevention trials more efficient link.springer.com/article/10.1...

Proud to be a part of the PrIMAVeRA consortium and contribute to developing comprehensive mathematical models to predict the impact of #vaccines and mAbs on reducing the burden of #anitmicrobialresistance 👇 🎉

📩 Our latest newsletter is out! We’re thrilled to welcome our new CEO, @lenniederde.bsky.social, marking a fresh chapter in Ecraid’s journey. Other updates in this edition: ✅ ECRAID-Base: new publications ✅ ECRAID-Prime: launch of third treatment arm And more… 📫 Subscribe now: bit.ly/NovEcraid

We are very pleased to announce Lennie Derde as Ecraid's new Chief Executive Officer effective 1 January 2026. She will succeed Ecraid’s co-founder @marcbonten.bsky.social Read more 👉 ecraid.eu/articles/len... @umcutrecht.bsky.social @ec.europa.eu @horizoneu.bsky.social

💉Early BCG vaccination could save newborn lives. A new RCT from India shows a nearly 20% drop in neonatal mortality simply by administering vaccines earlier. 🔗 Read the latest blog post by @marcbonten.bsky.social: letstalkscience.eu/2025/11/04/l... Join the discussion 👇🏽

💡 The Penta BFA provides recognition & funding to individuals driving change in maternal & child health. Honour a leader who is advancing equitable health outcomes & combatting infectious disease. Deadline for nominations has been extended to 15 November! 👉🏼 Submit your nomination: penta-id.org/bfa/

🚨 1 in 6 bacterial infections is now antibiotic-resistant. The new WHO GLASS Report demands immediate action. Ecraid is Europe's answer. We're bridging the crisis-to-solution gap. 👉🏽Read how: bit.ly/WHOGLASS

🦠 New tool to track #antibioticresistance: the Emerging Resistance Index (ERI). 💡Using data from 38 surveillance systems across Europe, researchers found rapid resistance emerging to all new Gram-negative antibiotics. The ERI could help guide surveillance & policy! 👉Read the article bit.ly/4hgk51g